Needham Reiterates Hold on Amicus Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Hold rating on Amicus Therapeutics (NASDAQ:FOLD).

August 09, 2024 | 9:34 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Gil Blum has reiterated a Hold rating on Amicus Therapeutics.
The reiteration of a Hold rating suggests that the analyst does not see significant upside or downside in the short term. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100